1. Introduction {#sec1}
===============

In advanced multiple myeloma, the choice of the treatment can be difficult, as therapeutic options decrease over time. Both new combinations of previously used drugs and retreatment with a previously adopted and effective therapy can be taken into consideration in patients showing persistent chemosensitivity. In this report, we describe the case of a heavily pretreated patient, refractory to bortezomib and IMIDs, with clinical benefit after retreatment with bendamustine.

2. Case Presentation {#sec2}
====================

In June 2009, this male patient was 67 years old and was diagnosed with IgG *λ* stage IIIA multiple myeloma (MM).*FISH analysis was performed at diagnosis, and it showed negativity for the most frequent alterations (t(11; 14), t(4; 14), del13q, and del17p)*. First-line therapy was 7 cycles of thalidomide-dexamethasone (TD), followed by radiotherapy on T2. In March 2010 progressive*bone* disease was detected by MRI of the spine showing multiple cervical and dorsal osteolytic lesions. Thus, second line of bortezomib-desametasone (VD), together with zoledronic acid, was performed for 5 cycles, obtaining a partial response. A first ASCT, preceded by thiotepa/melphalan conditioning regimen, was performed in December 2010 leading to a partial response. After a period with stable clinical conditions, in April 2011, disease progression*was documented by the increase of the serum monoclonal component (sMC)*: the patient was treated with 4 courses of lenalidomide-dexamethasone (RD), but the disease progressed. Therefore, a combination of melphalan-lenalidomide-dexamethasone (MRD) was performed for 3 cycles in September 2011, again followed by disease progression,*determined by sMC increase*. At the same time, PET/CT performed for neck pain revealed multiple osteolytic lesions: the most dangerous (C2) was treated with tomotherapy (40 Gy total). Thus, 2 cycles of cyclophosphamide-doxorubicin-dexamethasone (CED) regimen were attempted (1), but the disease was still refractory. Hence, a bendamustine-bortezomib-dexamethasone (BVD) regimen was administered (bendamustine 90 mg/sqm at days 1 and 2, bortezomib 1.3 mg/sqm at days 1, 4, 8, and 11, dexamethasone 20 mg at days 1, 2, 4, 5, 8, 9, 11, and 12, and pegfilgrastim 6 mg at day + 4) (2, 3, and 4) for 6 cycles, resulting in a partial response, followed by a second ASCT, preceded by thiotepa/melphalan conditioning regimen. In February*2014, a further sMC increase suggested disease progression, and* the patient was treated with bortezomib-lenalidomide-dexamethasone (VRD) for 6 cycles with the result of progressive disease. In November 2014, for disease progression confirmed also by PET/CT scan ([Table 1](#tab1){ref-type="table"}), even considering cardiovascular comorbidities, BVD-retreatment was chosen as tenth line. The patient switched to a stable disease status and clinical conditions were relatively fit for more than one year. The treatment was well tolerated: the only toxicities were grade 2 anemia and grade 3 thrombocytopenia, while severe neutropenia was effectively prevented with pegfilgrastim prophylaxis (6 mg at day + 4 of every courses). No extrahematological side effects were revealed.

Due to*further sMC increase*, in December 2015, 4 courses of pomalidomide-dexamethasone were attempted, in a palliative intent, but the patient died in July 2016.

3. Discussion {#sec3}
=============

After the advent of proteasome inhibitors, international guidelines agree on first-line treatment strategy for ASCT-eligible and noneligible patients \[[@B1]--[@B3]\]. However, selecting and managing the correct therapy for a patient with rrMM it is still a tough task for the hematologist, as, after many relapses, available therapeutic options are scanty. A commonly adopted strategy consists in retreating the patient with the same molecules used previously, choosing those which showed the best response or considering new drug combinations,*even if in previous administrations single drugs showed to be ineffective* \[[@B4]--[@B9]\].

This strategy seems particularly successful in patients who show persistent chemosensitivity, as in our case, who obtained an overall survival longer than 7 years, which can be considered as an impressive result in a 67-year-old patient affected by MM.

Bendamustine is a well-tolerated agent with a double mechanism of action, alkylating and antimetabolite, with proved effectiveness in treatment of relapsed/refractory \[[@B10], [@B11]\] and newly diagnosed multiple myeloma \[[@B12], [@B13]\] and in a relapsing/refractory setting \[[@B14]--[@B19]\]. In rrMM it can be used as single agent combined to dexamethasone, but a synergistic effect has been demonstrated when associated with bortezomib.

Bendamustine showed significant efficacy also in a selected setting of patients, such as those who became refractory to bortezomib and IMIDs or multirelapsed after single or double ASCT, demonstrating also an effective opportunity as a bridge to ASCT \[[@B10]\]. To the best of our knowledge, BVD-retreatment for relapsing/refractory MM is still not consolidated, but, as in our case, it could be considered an effective choice in heavily pretreated patients without significant therapeutic options, in a context of a well-tolerated palliative treatment with good quality of life.
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Patient\'s history.

  Line   Regimen                                      Cycle (n°)   Responses
  ------ -------------------------------------------- ------------ ---------------------
  1      Thalidomide-dexamethasone + RT               7            Progressive disease
  2      Bortezomib-dexamethasone                     5            Partial response
  3      First auto-BMT (thiotepa-melphalan)          /            Stable disease
  4      Lenalidomide-dexamethasone                   4            Progressive disease
  5      Melphalan-lenalidomide-dexamethasone         3            Progressive disease
  6      Doxorubicin-cyclophosphamide-dexamethasone   2            Progressive disease
  7      Bendamustine-bortezomib-dexamethasone        6            Partial response
  8      Second auto-BMT (thiotepa-melphalan)         /            Stable disease
  9      Bortezomib-lenalidomide-dexamethasone        6            Progressive disease
  10     Bendamustine-bortezomib-dexamethasone        7            Stable disease
  11     Pomalidomide-dexamethasone                   4            Progressive disease
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